2’-O-甲基肌苷 | 3881-21-8

• 物质功能分类: 生物化工 - 核苷类药物 - 核苷中间体
• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 中文名称: 2’-O-甲基肌苷
• 中文别名: 2‘-甲氧基肌苷；2'-甲氧基肌苷；2'-O-甲基肌苷
• 英文名称: 2'-O-methylinosine
• 英文别名: 9-[(2R,3R,4R,5R)-4-hydroxy-5-(hydroxymethyl)-3-methoxyoxolan-2-yl]-1H-purin-6-one
• CAS: 3881-21-8
• 化学式: C₁₁H₁₄N₄O₅
• 分子量: 282.256
• InChiKey: HPHXOIULGYVAKW-IOSLPCCCSA-N

物化性质

• 熔点：
  153-156 °C
• 沸点：
  724.3±60.0 °C(Predicted)
• 密度：
  1.84±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.8
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  118
• 氢给体数：
  3
• 氢受体数：
  7

制备方法与用途

9-((2R,3R,4R,5R)-4-羟基-5-(羟甲基)-3-甲氧基四氢呋喃-2-基)-9H-嘌呤-6-醇(2'-O-甲基肌苷)是一种嘌呤核苷类似物。这类化合物具有广泛的抗肿瘤活性，能够靶向惰性淋巴系统恶性肿瘤。其抗癌机制主要依赖于抑制DNA合成和诱导细胞凋亡等过程[1]。

反应信息

• 作为反应物：
  描述：

  2’-O-甲基肌苷 在 劳森试剂 、 吡啶 、 氨 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 甲醇 、 N,N-二甲基乙酰胺 为溶剂， 反应 51.0h， 生成 2'-O-methyl-1-propyl-6-thioinosine
  参考文献：
  名称：

  Antiviral Amphipathic Oligo- and Polyribonucleotides:  Analogue Development and Biological Studies

  摘要：

  A series of novel N1 alkylated purine nucleic acids were polymerized either enzymatically or by automated synthesis to further establish the SAR requirements for HIV, RT, and HCMV activity. Out of the series, two constructs, 2'-O-methyl-1-allylinosinic acid phosphorothioate 33-mer (16) and an oligomer incorporating 1-propyl-6-thioinosinic acid residues (20), were found to be highly active under all three assay conditions. SAR studies indicate that sulfur incorporation, high molecular weight, and low steric bulk at N1 all can be important for activity.

  DOI：

  10.1021/jm0203276
• 作为产物：
  描述：

  腺苷 在 sodium hydride 、 溶剂黄146 、 sodium nitrite 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 2’-O-甲基肌苷
  参考文献：
  名称：

  Antiviral Amphipathic Oligo- and Polyribonucleotides:  Analogue Development and Biological Studies

  摘要：

  A series of novel N1 alkylated purine nucleic acids were polymerized either enzymatically or by automated synthesis to further establish the SAR requirements for HIV, RT, and HCMV activity. Out of the series, two constructs, 2'-O-methyl-1-allylinosinic acid phosphorothioate 33-mer (16) and an oligomer incorporating 1-propyl-6-thioinosinic acid residues (20), were found to be highly active under all three assay conditions. SAR studies indicate that sulfur incorporation, high molecular weight, and low steric bulk at N1 all can be important for activity.

  DOI：

  10.1021/jm0203276

文献信息

• Noncanonical RNA Nucleosides as Molecular Fossils of an Early Earth-Generation by Prebiotic Methylations and Carbamoylations
  作者：Christina Schneider、Sidney Becker、Hidenori Okamura、Antony Crisp、Tynchtyk Amatov、Michael Stadlmeier、Thomas Carell

  DOI：10.1002/anie.201801919

  日期：2018.5.14

  prebiotic routes towards RNA. Contemporary RNA, however, is not only constructed from the four canonical nucleobases (A, C, G, and U), it also contains many chemically modified (noncanonical) bases. A still open question is whether these noncanonical bases were formed in parallel to the canonical bases (chemical origin) or later, when life demanded higher functional diversity (biological origin). Here

  RNA世界假说假设地球上的生命始于催化其自身形成的小RNA分子。对该假设至关重要的是，需要针对RNA的益生元途径。然而，当代RNA不仅由四个规范的核碱基（A，C，G和U）构建，而且还包含许多化学修饰的（非规范）碱基。一个尚待解决的问题是，当生命需要更高的功能多样性（生物起源）时，这些非规范碱基是否与规范碱基（化学起源）平行或更晚地形成。在这里，我们显示异氰酸酯与亚硝酸钠的组合建立了与地球早期条件相容的甲基化和氨基甲酰化反应性。这些反应导致仍然存在的甲基化和氨基酸修饰的核苷的形成。
• Nucleotide mimics and their prodrugs
  申请人：——

  公开号：US20040059104A1

  公开（公告）日：2004-03-25

  The present invention relates to nucleoside diphosphate mimics and nucleoside triphosphate mimics, which contain diphosphate or triphosphate moiety mimics and optionally sugar-modifications and/or base-modifications. The nucleotide mimics of the present invention, in a form of a pharmaceutically acceptable salt, a pharmaceutically acceptable prodrug, or a pharmaceutical formulation, are useful as antiviral, antimicrobial, and anticancer agents. The present invention provides a method for the treatment of viral infections, microbial infections, and proliferative disorders. The present invention also relates to pharmaceutical compositions comprising the compounds of the present invention optionally in combination with other pharmaceutically active agents.

  本发明涉及核苷二磷酸模拟物和核苷三磷酸模拟物，其中包含二磷酸或三磷酸基团模拟物，以及可选的糖修饰和/或碱基修饰。本发明的核苷酸模拟物，以药学上可接受的盐、药学上可接受的前药或药物配方的形式，可用作抗病毒、抗微生物和抗癌剂。本发明提供了一种治疗病毒感染、微生物感染和增生性疾病的方法。本发明还涉及包含本发明化合物的药物组合物，可选地与其他药理活性剂结合。
• [EN] RNAI AGENTS FOR INHIBITING EXPRESSION OF BETA-ENAC, COMPOSITIONS THEREOF, AND METHODS OF USE<br/>[FR] AGENTS D'ARNI POUR INHIBER L'EXPRESSION DE BETA-ENAC, LEURS COMPOSITIONS ET PROCÉDÉS D'UTILISATION
  申请人：ARROWHEAD PHARMACEUTICALS INC

  公开号：WO2021086995A1

  公开（公告）日：2021-05-06

  Described are RNAi agents, compositions that include RNAi agents, and methods for inhibition of a beta-ENaC (SCNN1B) gene. The beta-ENaC RNAi agents and RNAi agent conjugates disclosed herein inhibit the expression of a beta-ENaC gene. Pharmaceutical compositions that include one or more beta-ENaC RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the described beta-ENaC RNAi agents to epithelial cells, such as pulmonary epithelial cells, in vivo, provides for inhibition of beta-ENaC gene expression and a reduction in ENaC activity, which can provide a therapeutic benefit to subjects, including human subjects, for the treatment of various diseases including chronic obstructive pulmonary disease (COPD).

  描述了RNAi药剂、包含RNAi药剂的组合物，以及抑制β-ENaC（SCNN1B）基因的方法。本文披露的β-ENaC RNAi药剂和RNAi药剂结合物抑制了β-ENaC基因的表达。还描述了包含一个或多个β-ENaC RNAi药剂的药物组合物，可选地与一个或多个额外治疗药物一起使用。将所述的β-ENaC RNAi药剂传递至上皮细胞，如体内的肺上皮细胞，可实现抑制β-ENaC基因表达和减少ENaC活性，这可以为受试者，包括人类受试者，提供治疗益处，用于治疗包括慢性阻塞性肺疾病（COPD）在内的各种疾病。
• [EN] POLYNUCLEOTIDES ENCODING LIPOPROTEIN LIPASE FOR THE TREATMENT OF HYPERLIPIDEMIA<br/>[FR] POLYNUCLÉOTIDES CODANT POUR LA LIPOPROTÉINE LIPASE DESTINÉS AU TRAITEMENT DE L'HYPERLIPIDÉMIE
  申请人：MODERNATX INC

  公开号：WO2017201333A1

  公开（公告）日：2017-11-23

  The invention relates to mRNA therapy for the treatment of hyperlipidemia. mRNAs for use in the invention, when administered in vivo, encode human lipoprotein lipase (LPL), isoforms thereof, functional fragments thereof, and fusion proteins comprising LPL. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto, mRNA therapeaies of the invention increase and/or restore deficient levels of LPL expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of triglycerides associated with deficient LPL activity in subjects.

  该发明涉及mRNA疗法用于治疗高脂血症。该发明中使用的mRNA，在体内给予时，编码人类脂蛋白脂肪酶（LPL）、其异构体、其功能性片段以及包含LPL的融合蛋白。该发明中的mRNA最好被封装在脂质纳米颗粒（LNPs）中，以实现对受试者的细胞和/或组织的高效传递，当给予治疗时，该发明中的mRNA疗法增加和/或恢复受试者中LPL表达和/或活性的不足水平。该发明中的mRNA疗法进一步降低与受试者中LPL活性不足相关的甘油三酯水平。
• [EN] POLYNUCLEOTIDES ENCODING JAGGED1 FOR THE TREATMENT OF ALAGILLE SYNDROME<br/>[FR] POLYNUCLÉOTIDES CODANT POUR JAGGED1 POUR LE TRAITEMENT DU SYNDROME D'ALAGILLE
  申请人：MODERNATX INC

  公开号：WO2017201342A1

  公开（公告）日：2017-11-23

  The invention relates to mRNA therapy for the treatment of Alagille syndrome (ALGS), mRNAs for use in the invention, when administered in vivo, encode JAGGED 1 (JAG1), isoforms thereof, functional fragments thereof, and fusion proteins comprising JAG1, mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of JAG1 expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient JAG1 activity in subjects.

  该发明涉及用于治疗艾拉吉尔综合征（ALGS）的mRNA疗法，该发明中使用的mRNA，在体内给予时，编码JAGGED 1（JAG1）、其同工异构体、其功能性片段以及包含JAG1的融合蛋白，该发明的mRNA最好被封装在脂质纳米颗粒（LNPs）中，以实现对受试者的细胞和/或组织的有效传递，当向受试者施用时。该发明的mRNA疗法增加和/或恢复受试者中JAG1表达和/或活性的不足水平。该发明的mRNA疗法进一步降低与受试者中JAG1活性不足相关的有毒代谢物水平。